Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Hematology ; 25(1): 366-371, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33095117

RESUMO

OBJECTIVE: To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America. METHODS: This chart review study (NCT02559583; 2008-2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who initiate done (n = 261) to two (n = 96) lines of therapy (LOT) since diagnosis. Differences in TTP and OS were assessed by Kaplan-Meier analysis, with a log-rank test for statistical significance. Association between therapeutic regimen and risk for disease progression or death was estimated using Cox proportional hazard regression. RESULTS: The most commonly prescribed therapies in both LOTs were chlorambucil-, followed by fludarabine- and cyclophosphamide (C)/CHOP-based therapies. Chlorambucil- and C/CHOP-based therapies were largely prescribed to elderly patients (≥65 years) while fludarabine-based therapy was predominantly used by younger patients (≤65 years). In LOT1, relative to chlorambucil-administered patients, those prescribed fludarabine-based therapies had lower risk of disease progression (hazard ratio [HR] and 95% confidence interval [CI] 0.32 [0.19-0.54]), whereas C/CHOP-prescribed patients had higher risk (HR 95%CI 1.88 [1.17-3.04]). Similar results were observed in LOT2. There was no difference in OS between treatments in both LOTs. DISCUSSION: Novel therapies such as kinase inhibitors were rarely prescribed in LOT1 or LOT2in Latin America. The greater TTP observed forfludarabine-based therapies could be attributed to the fact that fludarabine-based therapies are predominantly administered to young and healthy patients. CONCLUSION: Chlorambucil-based therapy, which has limited benefits, is frequently prescribed in Latin America. Prescribing novel agents for fludarabine-based therapy-ineligible patients with CLL is the need of the hour. Trial registration: ClinicalTrials.gov identifier: NCT02559583.

2.
Br J Haematol ; 188(3): 383-393, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31392724

RESUMO

Limited data are available regarding contemporary multiple myeloma (MM) treatment practices in Latin America. In this retrospective cohort study, medical records were reviewed for a multinational cohort of 1103 Latin American MM patients (median age, 61 years) diagnosed in 2008-2015 who initiated first-line therapy (LOT1). Of these patients, 33·9% underwent autologous stem cell transplantation (ASCT). During follow-up, 501 (45·4%) and 129 (11·7%) patients initiated second- (LOT2) and third-line therapy (LOT3), respectively. In the LOT1 setting, from 2008 to 2015, there was a decrease in the use of thalidomide-based therapy, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, whereas use of bortezomib-based therapy or bortezomib + thalidomide increased from 10·7% to 45·5%. Bortezomib-based therapy and bortezomib + thalidomide were more commonly used in ASCT patients and in private clinics. In non-ASCT and ASCT patients, median progression-free survival (PFS) was 15·0 and 31·1 months following LOT1 and 10·9 and 9·5 months following LOT2, respectively. PFS was generally longer in patients treated with bortezomib-based or thalidomide-based therapy versus chemotherapy. These data shed light on recent trends in the management of MM in Latin America. Slower uptake of newer therapies in public clinics and poor PFS among patients with relapsed MM point to areas of unmet therapeutic need in Latin America.


Assuntos
Mieloma Múltiplo/terapia , Padrões de Prática Médica/estatística & dados numéricos , Adulto , Fatores Etários , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bortezomib/administração & dosagem , Comorbidade , Uso de Medicamentos/estatística & dados numéricos , Feminino , Seguimentos , Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Humanos , Estimativa de Kaplan-Meier , América Latina/epidemiologia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/epidemiologia , Instalações Privadas/estatística & dados numéricos , Logradouros Públicos/estatística & dados numéricos , Estudos Retrospectivos , Talidomida/administração & dosagem , Resultado do Tratamento
3.
J Glob Oncol ; 5: 1-19, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31774711

RESUMO

PURPOSE: Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. METHODS: This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). RESULTS: Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. CONCLUSION: The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.


Assuntos
Leucemia Linfocítica Crônica de Células B/epidemiologia , Linfoma não Hodgkin/epidemiologia , Mieloma Múltiplo/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Humanos , América Latina/epidemiologia , Pessoa de Meia-Idade , Sistema de Registros , Adulto Jovem
4.
Bol. Acad. Nac. Med. B.Aires ; 87(2): 239-246, jul.-dic. 2009. tab
Artigo em Espanhol | LILACS | ID: lil-606183

RESUMO

El manejo convencional de los síndromes mieloproliferativos crónicos (SMP) es un problema cuya frecuencia se ha incrementado. Los datos existentes en la literatura provienen principalmente de series de casos. Esta serie reporta la evolución y el tratamiento de 9 embarazos en 7 pacientes con SMP, 4 con diagnóstico de leucemia mieloide crónica (LMC) y 3 con trombocitemia esencial (TE) asistidos en nuestro Departamento durante los últimos 20 años. La evolución del primer embarazo incluyó: nacido vivo a término 29 por ciento, aborto espontáneo 14 por ciento, nacido vivo pretérmino 29 por ciento y desconocida 14 por ciento. Un embarazo está en curso (14 por ciento). No se registraron muertes fetales. Las complicaciones maternas fueron: sangrado en una paciente con LMC y desprendimiento placentario en otro caso con TE. La segunda gestación resultó en un nacido vivo pretérmino (N=1) y otra está en curso. Todas las pacientes con TE recibieron interferón alta y aspirina durante el embarazo y profilaxis con enoxaparina durante el puerperio. Las pacientes con LMC recibieron: interferón alfa (N=1), hidroxiurea luego del primer trimestre e interferón alfa (N= 1) e imatinib durante el primer trimestre y nilotinib en el tercero la tercer paciente, dando a luz un feto vivo normal. Un mayor número de casos sería necesario para establecer factores pronósticos en este grupo de pacientes.


Chronic myeloproliferative syndromes and pregnancy. A case review of Clinical Hematological Department patients. The management of pregnancy in chronic myeloproliferative disorders (CMPD) is an increasingly frequent problem. Available data in the literature belong to case reports or single centers series. In the current study we report the outcome and treatment of 9 pregnancies among 7 patients with CMPD, 4 with chronic myeloid leukemia (CML) and 3 with essential thrombocythemia (ET) seen in our Department from 1989 to 2009. First pregnancy outcome included full term normal delivery 29 per cent, spontaneous abortion 14 per cent, premature delivery 29 per cent and unknown 14 per cent. No stillbirth was recorded and one pregnancy is currently ongoing. Maternal complications included: bleeding in one CML patient and abruptio placentae in a TE patient. Among second pregnancies, 1 is ongoing and the other resulted in premature delivery. AII TE patients received alpha interferon and aspirin during pregnancy. Prophylaxis with enoxaparin was administered for six weeks postpartum. CML patient were treated as follows: alpha interferon (N=1), hydroxyurea after first trimester plus alpha interferon (N=1). The remaining patient received imatinib and nilotinib giving birth to a normal baby. Further study is necessary to evaluate prognostic factors in these patients.


Assuntos
Humanos , Adulto , Feminino , Gravidez , Complicações Hematológicas na Gravidez , Transtornos Mieloproliferativos/complicações , Transtornos Mieloproliferativos/terapia , Doença Crônica , Evolução Clínica , Técnicas de Laboratório Clínico , /genética , Leucemia Mielogênica Crônica BCR-ABL Positiva , Trombocitemia Essencial
5.
Bol. Acad. Nac. Med. B.Aires ; 84(2): 305-315, jul.-dic. 2006. tab
Artigo em Espanhol | LILACS | ID: lil-567714

RESUMO

La resistencia al tratamiento con Imatinib resulta de mecanismos dependientes del BCR/ABL tales como la sobreexpresión y la adquisición de mutaciones de punto en sitios críticos del dominio kinasa de ABL o de diferentes mecanismos independientes, como la evolución clonal. El propósito de este estudio fue identificar las mutaciones del dominio kinasa del gen ABL y la amplificación del reordenamiento genómico BCR/ABL en pacientes con LMC con falta o pérdida de respuesta hematológica y/o citogenética al tratamiento con Imatinib. Se incluyeron 71 pacientes, de los cuales 56 fueron evaluables. En trece pacientes (24 por ciento) se identificó algún mecanismo de resistencia: 10 (18 por ciento) presentaron mutaciones de punto en el dominio kinasa, 3 (5 por ciento) duplicación del cromosoma Ph' y sólo 1 (1 por ciento) mostró amplificación del BCR/ABL. La mutación T315I se observó en 1 caso. La mediana de edad fue significativamente menor [39 años (20-53)] en los pacientes en los que se encontraron mutaciones que en los casos sin ellas [51 años (24-75)] p=0.047. Se detectaron mutaciones en 1 de 29 (3 por ciento) pacientes en fase crónica, 8 de 20 (40 por ciento) pacientes en fase acelerada y en 1 de 8 (12 por ciento) pacientes en crisis blástica (p=0.001). La mediana de aparición de las mismas fue de 45 meses desde el diagnóstico de LMC (12-158) y 28.5 meses (1-56) desde el inicio de la terapia con Imatinib (p=0.591 y p=0.762 respectivamente). Las mutaciones en la región p-loop fueron las más frecuentes. El análisis univariado demostró que edad y fase de la enfermedad se asociaron significativamente con presencia de mutaciones. Las mutaciones en el dominio kinasa se reconocen como el principal mecanismo de resistencia al tratamiento con Imatinib y su detección puede determinar un cambio en la estrategia terapéutica.


Assuntos
Humanos , Masculino , Adulto , Feminino , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Piperazinas/farmacologia , Pirimidinas/farmacologia , Antineoplásicos , Genes abl , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Mutação Puntual , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Resistencia a Medicamentos Antineoplásicos/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA